Name | CCG-1423 |
Description | CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription. |
Cell Research | Cells in normal culture medium are plated (2,000 per well) in a 96-well plate coated with laminin. After attachment, the medium is replaced with serum-free medium (0% FBS) with 30 μmol/L LPA with or without 300 nM CCG-1423. Fresh LPA with or without CCG-1423 is added at day 5 to ensure that LPA and compound are present throughout the experiment. On day 8, WST-1 reagent is added to the wells for 1 h and absorbance at 450 nm is read using a Victor plate reader.(Only for Reference) |
In vivo | In H9c2 cells, CCG-1423 inhibits MRTF nuclear localization and completely blocks the activity of STARS proximal reporter genes. It also suppresses TGF-β-induced fibrogenesis in human colon myofibroblasts. Under the influence of CCG-1423 and LY294002, mouse embryonic stem cells differentiate into the mesendoderm. In melanoma cells (A375M2 and SK-Mel-147) overexpressing RhoC, CCG-1423 selectively inhibits cell proliferation. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 4 mg/mL (8.79 mM), Heating is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 83 mg/mL (182.5 mM)
|
Keywords | PC-3 | conformational restriction | mice | Inhibitor | bioisostere | CCG-1423 | CCG 1423 | glucose tolerance | metastasis | Apoptosis | inhibit | prostate,serum | Ras |
Inhibitors Related | Adagrasib | BI-2493 | CCG-257081 | Ketoconazole | SKLB-163 | MRTX1133 | Salirasib | GNE-7915 | RMC-6236 | (S)-(-)-Perillyl alcohol | CASIN | Sotorasib |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |